Polymer-of-prodrug (POP) materials enable new nucleoside reverse transcriptase inhibitor (NRTI) therapy strategies. The materials are prodrugs of NRTIs in the form of polymers. Suitable materials include products which are polymeric NRTI delivery systems comprising polymeric materials which are capable of degradation after administration to release NRTIs or NRTI prodrugs which themselves are capable of metabolism to the parent NRTIs. The NRTIs may optionally be selected from tenofovir (TFV), emtricitabine (FTC), lamivudine (3TC) and MK-8591 (EFdA). The invention facilitates long-acting (LA) regimens. Constructs of the materials may be in the form of injectable compositions or implants.
聚合物前药(POP)材料实现了新的核苷类逆转录酶
抑制剂(NRTI)治疗策略。这些材料是核苷类逆转录酶
抑制剂的前药,以聚合物的形式存在。适用材料包括聚合物NRTI传递系统的产品,其中包括能够在给药后降解以释放NRTIs或NRTI前药的聚合物材料,这些NRTIs本身能够代谢成母体NRTIs。NRTIs可以选择自
替诺福韦(TFV)、恩曲替滨(FTC)、
拉米夫定(3TC)和MK-8591(EFdA)。该发明促进了长效(
LA)疗程。这些材料的构造可以是注射剂或植入物的形式。